GUANIDINE COMPOUNDS, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM

Abstract: The present invention provides compounds of formula (I): and pharmaceutically acceptable salts thereof, which have his­ tamine H₂-antagonist activity. In formula (I) Z is sulphur or methylene and R¹ is hydrogen, C₁₋₄alkyl, optionally substituted phenyl or phenyl (C₁₋₄ alkyl) (the substituents being one or more C₁₋₄ alkyl, or C₁₋₄ alkoxy groups or halogen atoms or a methylenedioxy group), or optionally substituted furanyl-, thie­ nyl, or pyridyl- (C₁₋₄ alkyl) (the substituents being one or more C₁₋₄ alkyl or C₁₋₄ alkoxy groups); and R² is hydrogen, C₁₋₄ alkyl or benzyl. One particular compound of formula (I) is 2-[2-(2-guanidi­ no-4-thiazolylmethylthio)] ethylamino-3-nitro pyrrole.

Description: GUANIDINE COMPOUNDS, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM This invention relates to guanidine compounds having histamine H2-antagonist activity, their preparation, and pharmaceutical compositions containing them. Histamine, a physiologically active compound endogenous in mammals , exerts. its action by interacting with certain sites called receptors. One type of receptor is known as a histamine H1-receptor (Ash and Schild1 Brit. J. Pharmac. 1966, 27, 427) and the actions of histamine mediated through these receptors are blocked by drugs commonly called "antihistamines (histamine H1antagonists) a common example of which is mepyramine. A second type of histamine receptor is known as the H2receptor (Black et al. Nature 1972, 236, 385). These receptors are not blocked by mepyramine but are blocked by burimamide. Compounds which block these histamine H2- receptors are called histamine H2-antagonists. Histamine H2-antagonists are useful in treating disease conditions caused by the biological effects of histamine mediated through H2-receptors, for example, as inhibitors of gastric acid secretion, in the treatment of inflammation mediated through histamine H2-receptors and as agents which act on the cardiovascular system, for example, as inhibitors of effects of histamine on blood pressure mediated through histamine H2-receptors. Cimetidine is an example of a histamine H2-antagonist. Cimetidine has been shown to be useful in the treatment of duodenal, gastric, recurrent and stomal ulceration, and reflux oesophagitis and in the management of patients who are at high risk from haemorrhage of the upper gastrointestinal tract. In some. physiological conditions the biological actions of histamine are mediated through both histamne H7 and H2-receptors and blockade of both. types of receptors is useful These conditions include inflammation mediated by histamine, for example skin inflammation, and those hypersensitivity responses due to the action of histamine at H1- and H2-receptors, for example allergies. A class of gianidine derivatives has now been discovered which are particularly active as histamine Hz- antagonists Accordingly, the present invention provides compounds of formula (I) EMI2.1 and pharmaceutically acceptable acid addition salts thereof, where Z is sulphur or methylene and R1 is hydrogen; C14 alkyl; optionally substituted phenyl or phenyl (C1 4 alkyl) (the substituents being one or more C 1-4 alkyl, or C1-4 alkoxy groups or halogen atoms or a methylenedioxy group), or optionally substituted furanyl-, thienyl-, or pyridyl (Cl 4 aLkyl) (the substituents being one or more C14 alkyl or C1-4 alkoxy groups);' and R2 is hydrogen, C1-4 alkyl or benzyl Examples of substituted phenyl groups and the substituted phenyl moiety of phenyl (C14 alkyl) groups for R are 3-methylphenyl; 3-methoxyphenyl; 3,4-dimethoxyphenyl and 3-chlorophenyl. Examples of optionally substituted furanyl, thienyl and pyridyl (C1-4 alkyl) groups for Rl are optionally substituted 2-furanyl-, 2-thienyl-, 2-pyridyl-, 3-pyridyl-, or 4-pyridyl-(C1 4 alkyl) groups, and particularly 3-pyridyl-, 6-methyl-3-pyridyl- and 6-methoxy-3-pyridyl (C1-4 alkyl). Preferably R1 is hydrogen. Preferably R is hydrogen. Preferably Z is sulphur. Pharmaceutically acceptable acid addition salts of the compounds of formula (I) include those formed with hydrochloric, hydrobromic, hydroiododic, sulphuric and maleic acids. Preferably the compound is in the form of the free base The compounds of the invention can be prepared by reacting a compound of formula (II): EMI3.1 where Y is either Z(CH2)2NH2 or, when Z in the compound of formula (I) is sulphur, a leaving group displaceable by mercaptan, with a compound of formula (III): EMI3.2 where X is a leaving group displaceable with an amine when Y is Z(CH2)2NH2 or HS(CH2)2NH- when Y is a leaving group displaceable by mercaptan; and R and R are as defined with reference to formula (I), and thereafter optionally converting the compound of formula (I) so obtained into a salt. Examples of leaving groups displacable by mercaptan are halogen, trisubstituted phosphonium (for example tri-phenylpho.sphonium) or substituted sulphonyloxy (for example, p-toluenesulphonyloxy, methanesulphonyloxy or trifluoromethanesulphonyloxy) Examples of leaving groups displacable by amines are where X is QSOF or QS02- (Q being C14 alkyl, aryl or alkyl) Preferably the group X is QSO where Q is methyl or benyl The process where' X is a leaving group displaceable by amines is preferably carried out in the presence of a solvent for example a C14 alkanol. In general, an elevated temperature will be used, for example, the boiling point of the reaction mixture. Acid addition salts of compounds of formula (I) can conveniently be formed from the corresponding bases by standard procedures for example by reacting the base with an acid in a C1 4 alkanol or by the use of ion exchange resins to form the required salt. Salts of compounds of formula (I) can also be interconverted using an ion exchange resin. The compounds of formula (I) and the intermediate compounds of formula (III) where X is QSO or QSO 2 can be prepared by reacting a compound of formula (IV) :- EMI5.1 where E is EMI5.2 or QS- and xlis QS, or QSO when E is QS-, with a compound of formula (V): EMI5.3 where R1 and R2 are as defined with reference to formula (I) and R3 and R4 are C 1-4 alkoxy groups or together represent an oxygen atom; optionally converting a compound of formula (I) so obtained into a salt or oxidizing a compound of formula (III) so obtained where X is QS-. When compound (V) is used, where R3 and R together represent an oxygen atom, the reaction will in general be carried out under basic conditions, for example with sodium ethoxide in ethanol. When a compound (V) is used where R3 and R4 are C1-4 alkoxy, the reaction is preferably carried out under neutral conditions, for example, in boiling ethanol, and the product cyclised under acidic conditions, for example by treatment with hydrogen chloride in a solvent (for example ether or a C 1-4 alkanol). An intermediate (III) obtained by this process where X is QS- can be oxidised with one equivalent of hydrogen peroxide, to an intermediate (III) where X is QSO- and to an intermediate (III) where X is QS02- by reaction with two or more equivalents of hydrogen peroxide. The intermediates of formula (III) where X is HS (CH2) 2NH- can be prepared by reacting a compound of formula (III) where X is QSO- or QS02- with an amine of formula HS(CH2)2NH2 The activity of the compounds of formula (I) as histamine H2- antagonists can be demonstrated by the inhibition of histamine-stimulated secretion. of gastric acid from the lumen-perfused stomachs of rats anaesthetised with urethane. This procedure is referred to in Ash and Schild, Brit. J. Pharmac. Chemother., 1966. 27. 247 The compound of Example I hereafter caused 50% inhibition of maximal acid secretion at doses of less than OL1 micromole kç 1 i.v. Their activity as histamine H2- antagonists can also be demonstrated by their ability to inhibit other actions of histamine which, according to the above mentioned paper of Ash and Schild, are not mediated by histamine H1-receptors. For example, they inhibit the actions of histamine on the isolated guinea pig atrium. The potency of these compounds is illustrated by the effective dose producing 50% inhibition of the histamine-induced tachycardia in the isolated guinea pig atrium (less than 10 6 Molar Example 1). In order to use compounds of formula (I) or a pharmaceutically acceptable salt thereof for medical purposes, they are normally formulated in accordance with standard pharmaceutical practice as pharmaceutical compositions. The invention further provides pharmaceutical compositions .comprising a compound of formula (I) above or a pharmaceutically acceptable acid addition salt thereof together with a pharmaceutically acceptable carrier. Compounds of formula (I) and their pharmaceutically acceptable acid addition salts may be administered orally, parenterally, cutaneously or rectally. Compounds of formula (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as syrups, tablets, capsules and lozenges. A syrup formulation will generally consist of a suspension or solution of the compound or salt in a suitable liquid carrier for example, ethanol glycerine or water with a flavouring or colouring agent. Where the composition is in the form of a tablet, any suitable pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose-. Typical parenteral compositions consist of a solution or suspension of the compound or salt in a sterile aqueous carrier or parenterally acceptable oil. Typical compositions for administration to the skin include lotions and creams in which the compound of formula (I) or salt thereof is contained in a liquid vehicle. A typical suppository formulation comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent such as gelatin or cocoa butter or other low melting vegetable waxes or fats. Preferably the composition is in unit dose form such as a tablet or capsule so that the patient may administer to himself a single dose. Each dosage unit contains preferably from 15 to 250 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base. The pharmaceutical compositions of the invention will normally be administered to man for the treatment of peptic ulcers and other conditions caused or exacerbated by gastric acidity in the same general manner as that employed for known histamine H2-antagonists, due allowance being made in terms of dose levels for the potency of the compound of the present invention relative to known histamine H2-antagonists. Thus an adult patient will receive an oral dose of between 15 mg and 1500 mg and preferably between 20 mg and 250 mg or an intravenous, subcutaneous or intramuscular dose of between 1.5 mg and 150 mg, and preferably between 5 mg and 20 mg of compound of formula (I) or pharmaceutically acceptable salt thereof calculated as the free base, the composition being administered 1. to 6 times per day. The following Examples illustrate the invention. Examples Example 1 Examples 2-S2-(2-Guanidino-4-thiazolylmethylthio)ethvlamino7- 3-nitropyrrole A solution of 2-(2-guanidino-4-thiazolylmethylthio) 'ethylamine dihydrochloride (4g, 0.013 mole) in ethanol (25 ml) was basified with a solution of sodium (0.65g, 0.028 mole) in ethanol (20 ml). The mixture was filtered and the filtrate added to 2-methylsulphinyl 3-nitropyrrole (1.5g, 0.0086 mole). The mixture was refluxed for 5 days, then the solvent was removed in vacuo and the residue chromatographed on a silica-gel column. The product was eluded with ethyl acetate/propan-2-ol (8:2) and recrystallised from methanol/acetone (6:4). Yield: 0.65g, 22%. M.P. 195.5 - 2000C. Example 2 2- [2-(2-Guanidino-4-thiazolylmethylthio) ethylaminc] -4-methyl-3-nitropyrrole The title compound is prepared from 2-(2-Guanidino-4 thiazolylmethylthio)-ethylamine dihydrochloride and 2-methylsulphinyl-4-methyl-3-nitropyrrole by a process analogous to that described in Example 1. Example 3 2- J4- (2-Guanidino-4-thiazolyl) butylamino- 3-nitroyrrole The title compound is prepared from 4-(2-guanidino 4-thiazolyl) butylamine dihydrochloride and 2-methylsul phinyl-3-nitropyrrole by a process analogous to that described in Example 1.

Claims: CLAIMS 1. A compound of formula (I) : EMI10.1 and pharmaceutically acceptable acid addition salts thereof, where Z is sulphur or methylene and R1 is hydrogen; C1-4 alkyl, optionally substituted phenyl or phenyl (C1-4 alkyl), (the substituents being one or more C14 alkyl or C14 alkoxy groups or halogen atoms or a methylenedioxo group), or optionally substituted furanyl- or thienyl- or pyridyl (C1 4 alkyl) the substituents being one or more C14 alkyl or C14 alkoxy groups); and R is hydrogen, C1 4 alkyl or benzyl. 2. A compound as claimed in Claim I where R1 is 3-methylphenyl; 3-methoxyphenyl; 3,4-dimethoxyphenyl or 3 -chlorophenyl 3. A compound as claimed in Claim 1 or Claim 2 where the optionally substituted furanyl-, thienyl- or pyridyl (C1-4 alkyl) group R1 is an optionally substituted 2furanyl-, 2-thienyl-, -3-pyridyl or' 4-pyridyl (C1 4¯alkyl) group. 4. A compound as claimed in any one of Claims 1 to 3 where R1 is 3-pyridyl-, 6-methyl-3-pyridyl-, or 6-methoxy3-pyridyl (C14 alkyl). 5. A compound as claimed in anyone of Claims 1 to 4 where R1 is hydrogen. 6. A compound as claimed in anyone of Claim 1 to 5 where R2 is hydrogen. 7. A compound according to any one of Claims 1 to 6 where Z is sulphur. 8. 2-[Z-(2-Guanidino-4-thiazolylmethylthio)-ethyl- amino I-3-nitropyrrole , 2-[2-(2-Guanidino-4-thiazolylmethylthio)-ethyl- amino]-4-methyl-3-nitropyrrole and 2-[2-(2-Guanidino-4-thiazolylmethylthio)butyl- amino I - 3 -nitropyrrole . 9. A process for preparing a compound as claimed in claim 1 which comprises reacting 8 compound of formula (II): EMI11.1 where Y is either Z(CH2)2NH2 or, when Z in the compound of formula (I) is sulphur, a leaving group displaceable by mercaptan, with a compound of formula (III) EMI11.2 where X is a leaving group displaceable with an amine when Y is Z(CH2)2NH2, or HS(CH2)2NH- when Y is a leaving group displaceable by mercaptan; and R1 and R2 are as defined with reference to formula (I), and thereafter optionally converting the compound of formula (I) so obtained into a salt. 10. A process for preparing a compound as claimed in claim 1 which comprises reacting a compound of formula (IV) : EMI12.1 where E is EMI12.2 with a compound of formula (V) EMI12.3 where-Rl and R2 are as defined with reference to formula (I) and R3 and R4 are lower alkoxy groups or together represent an oxygen atom; optionally converting a compound of formula (I) so obtained into a salt. 11. A pharmaceutical composition comprising a compound as claimed in anyone of claims 1 to 8 and a pharmaceutically acceptable carrier. 1. A process for preparing a compound of formula (I) : EMI13.1 and pharmaceutically acceptable acid addition salts thereof, where Z is sulphur or methylene and R1 is hydrogen; C1-4 alkyl, optionally substituted phenyl or phenyl (C 1-4 alkyl), (the substituents being one or more C1-4 alkyl or C14 alkoxy groups or halogen atoms or a methylenedioxo group), or optionally substituted furanyl- or thienyl- or pyridyl (C1 4 alkyl) the substituents being one or more C1 4 alkyl or C1-4 alkoxy groups); and R2 is hydrogen, Cl 4 alkyl which comprises either (a) reacting a compound of formula (II) EMI13.2 where Y is either Z(CH2)2NH2 or, when Z in the compound of formula (I) is sulphur, a leaving group displaceable by mercaptan, with a compound of formula (III) EMI13.3 where X is a leaving group displaceable with an amine when Y is Z(CH2)2NH2, or HS(CH2)2NH- when Y is a leaving group displaceable by mercaptan; and R1 and R2 are as defined with reference to formula (I), or (b) reacting a compound of formula (it) : EMI14.1 where E is EMI14.2 or QS- and X is QS, or QSO with a compound of formula (V) : EMI14.3 where R1 and R2 are as defined with reference to formula (I) and R3 and R4 are C14 alkoxy groups or together represent an oxygen atom; optionally converting a compound of formula (I) so obtained in step (a) or step (b) into a salt. 2. A process as claimed in Claim 1 where R1 in the compound of formula (I) is 3-methyl-phenyl; 3-methoxyphenyl; 3,4-dimethoxyphenyl or 3-chlorophenyl. 3. A process as claimed in Claim 1 or Claim 2 where the optionally substituted furanyl-, thienyl- or pyridyl (C1 4 alkyl) group R1 in the compound of formula (I) produced is an optionally substituted 2-furanyl-, 2-thienyl-3-pyridyl or 4-pyridyl (Cl 4 alkyl) group. 4. A process as claimed in any one of Claims 1 to 3 where Rl in the compound of formula (I) produced is 3-pyridyl-, 6-methyl-3-pyridyl-, or 6-methoxy-3-pyridyl (C1-4 alkyl). 5. A process as claimed in anyone of Claims 1 to 4 where R1 in the compound of formula (I) produced is hydrogen. 6. A process as claimed in anyone of Claims 1 to 5 in the compound of formula (I) produced is hydrogen. 7. A process according to anyone of Claims 1 to 6 where Z in the compound of formula (I) produced is sulphur. 8 A process as claimed in Claim 1 where the product in the compound of formula (I) produced is 2-[2-(2-Guanidino 4-thiazolylethylthio) -ethylamino -3-nitropyrrole, 2-[Z-(2-Guanidino-4-thiazolylmethylthio)-ethylamino3- 4-methyl-3 -nitropyrrole or 2-[2-(2-Guanidino-4-thiazolylmethylthio)butylamino]-3- nitropyrrole.

Inventors: ROANTREE, MICHAEL LAURENCE, YOUNG, RODNEY CHRISTOPHER
Applicants: SMITH KLINE & FRENCH LABORATORIES LIMITED
Application year: 1980
Main classification: C07D417
IPC codes: A61P43, A61K31, C07D417